Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03265522
Other study ID # 16/NI/0105
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2017
Est. completion date June 30, 2019

Study information

Verified date November 2019
Source Queen's University, Belfast
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evidence suggests that a Mediterranean diet can have a beneficial effect on brain health. Mild cognitive impairment (MCI) describes problems with brain function such as difficulty with day-to-day memory and concentration. It is at this stage that Mediterranean diet could prove beneficial in terms of prevention.

Previous research by Queens University investigated the opinions of patients with MCI and their care givers to inform the development of Mediterranean diet education material to encourage behaviour change. The study suggested that MCI patients lacked awareness of the link between Mediterranean diet and brain function, although were interested to learn more. Feedback on the developed educational material was positive although there were suggested improvements such as tailoring information to memory loss, a potential staged approach to delivery and adaptations to the material content.

This present study aims to pilot test refined educational material among MCI participants to evaluate the feasibility of encouraging dietary behaviour change among this patient group.


Description:

This study aims to evaluate the feasibility of a theory-based, tailored Mediterranean lifestyle education intervention to encourage behaviour change in patients with MCI. The proposed study will be a 6 month RCT with a total of 60 MCI patients who will be randomised to 1 of 3 groups:

1. Group 1 will receive the Mediterranean lifestyle education resource on one occasion at baseline

2. Group 2 will receive the Mediterranean lifestyle education resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian

3. Group 3 will receive standard care (control group). Participants will receive the Mediterranean lifestyle education resource after their final 6 month study visit (i.e. delayed intervention).


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date June 30, 2019
Est. primary completion date June 30, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria

- Diagnosis of Mild Cognitive Impairment by their physician

- Mediterranean diet score (MDS) less than or equal to 4 (Estruch et al., 2006)

- Willing to make changes to their diet

Exclusion Criteria:

- Diagnosis of dementia

- Patients with visual or English language impairment

- Psychiatric problems

- Significant medical comorbidity

- Body Mass Index (BMI) = 19 and = 40 kg/m2

- Excessive alcohol consumption

- Taking high dose nutritional supplements

- Dietary restrictions/allergies that would substantially limit ability to complete study requirements

- Inability to provide informed consent

- History of, or comorbid condition which may alter performance on cognitive tests e.g. stroke, head injury, Parkinson's disease, learning disability

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
"ThinkMed" resource at baseline
The "ThinkMed" resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline.
Standard Care Control
Participants will continue with the standard care provided by their physician. Participants will receive the "ThinkMed" resource after their final 6 month study visit (i.e. delayed intervention).
"ThinkMed" resource (staged)
This group of participants will receive the "ThinkMed" resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian

Locations

Country Name City State
United Kingdom Belfast Health and Social Care Trust Belfast

Sponsors (2)

Lead Sponsor Collaborator
Queen's University, Belfast Wellcome Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Process Evaluation (1) - telephone contact evaluation Determination individual participation and engagement with the intervention by reviewing telephone contact log record and telephone checklist evaluation up to 3 months post intervention
Other Process Evaluation (2) - study records A review of study records- including attrition rates, reason for dropout up to 3 months post intervention
Other Process Evaluation (3) - structured interviews Post intervention structured interviews for participant evaluation of the intervention programme and dietary educational materials up to 3 months post intervention
Primary Change in Mediterranean Diet Score (MDS) at 6 months Mediterranean dietary intake will be measured by a validated questionnaire Baseline, 6 months
Secondary Physical Activity RPAQ-Recent Physical Activity Questionnaire Baseline, 6 months
Secondary Anthropometric measurements Weight and height measurements to calculate BMI Baseline, 6 months
Secondary Muscle Strength Measured using a grip-strength dynamometer Baseline, 6 months
Secondary Geriatric Depression Scale Geriatric Depression Scale Questionnaire Baseline, 6 months
Secondary Functional Assessment (1) Measured by the instrumental activities of daily living scale (IADL) by Lawton and Brody (1969) questionnaire Baseline, 6 months
Secondary Cognitive Assessment A comprehensive cognitive assessment will be performed, including: global cognition, motor skills, executive function episodic/visual memory, and information processing and sustained attention using a validated neuropsychological test battery (Cantab Cognitive Battery, Cambridge Cognition Ltd.) Baseline, 6 months
Secondary Barriers to consuming a Mediterranean Diet questionnaire Dietary behaviour change questionnaire to measure adherence to a Mediterranean diet Baseline, 6 months
Secondary Blood Sample A blood sample will be taken from participants to be stored for analysis of biomarkers of MD adherence and biomarkers of neurodegenerative disease risk. Baseline, 6 months
Secondary Functional Assessment (2) Measured by the Bristol activities of daily living scale (Bucks et al. 1996) questionnaire Baseline, 6 months
Secondary 4-day Food Diary A food diary will be completed to assess compliance with a Mediterranean diet Baseline, 6 months
Secondary Change in Lifestyle questionnaire A questionnaire to measure change in lifestyle behaviours Baseline, 6 months
Secondary Dietary Quality of Life questionnaire A questionnaire to measure dietary quality of life Baseline, 6 months
Secondary Mediterranean Diet Knowledge questionnaire A questionnaire to measure participants Mediterranean diet knowledge Baseline, 6 months
Secondary Rand SF-36 HEALTH SURVEY A questionnaire to measure participants views and beliefs on health Baseline, 6 months
Secondary Staging Algorithm Questionnaire A questionnaire to measure participants readiness to change their diet and lifestyle Baseline, 6 months
Secondary Mediterranean Diet self-efficacy questionnaire A questionnaire to measure participants self-efficacy Baseline, 6 months
Secondary Mediterranean diet tolerance questionnaire A questionnaire to measure tolerance to a Mediterranean diet Baseline, 6 months
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A